Vertex Pharmaceuticals Incorporated’s stock price (VRTX) fell in the intraday levels amid the dominance of the downward correctional trend in the short term, with negative pressure from the 50-day SMA, coupled with negative signals from the RSI after reaching overbought levels compared to the stock’s movements, hinting at negative divergence, which could double negative pressures on the stock.
Therefore we expect more losses for the stock, targeting the first support at 407.00, provided it settles below 427.40.
Stay updated on market developments for informed investment decisions.